QUOTE AND NEWS
FierceBiotech  Aug 26  Comment 
Former Elan CEO Kelly Martin is back at the helm of a business. The controversial dealmaker has taken over as CEO of Malin, the life science investment fund he helped to set up and guide to a €330 million ($380 million) IPO earlier this year.
Reuters  Jul 29  Comment 
Slovenian state firm SDH, which is coordinating privatisation, approved the sale of state-owned ski maker Elan to Merrill Lynch International and Wiltan Enterprises...
Bulk Transporter  Jul 8  Comment 
MAUSER Group, a worldwide leading company in industrial packaging based in Bruehl, Germany, acquired a 50% shareholding of Time Technoplast in the intermodal bulk container (IBC) business of Fanshun Elan. The acquisition was effective July 1,...
Reuters  Jul 3  Comment 
Two bomb blasts in Colombia's capital Bogota on Thursday were likely the work of the smaller of the country's two leftist rebel groups, the National Liberation Army or ELN, President Juan Manuel Santos said.
Reuters  Apr 28  Comment 
A federal judge dismissed claims by former Elan Corp and Wyeth shareholders accusing billionaire investor Steven A. Cohen's SAC Capital Advisors LP of violating federal...
FierceBiotech  Mar 17  Comment 
Neil Woodford's fund has committed to buy shares in Malin, the life science investment company set up by Kelly Martin and other former Elan executives. And with Woodford, the Ireland Strategic Investment Fund and other cornerstone investors...
Forbes  Mar 11  Comment 
At a distance, the Apple Watch is an elegant must-have doodad. It's as sleek as a supermodel and its geekiness is expressed with stealth and elan.
FierceBiotech  Mar 9  Comment 
Alkermes is selling off a manufacturing plant in a deal worth up to $170 million, cashing out of some royalty streams to better invest in its late-stage pipeline of new therapies.
GenEng News  Feb 27  Comment 
Integration of (and interoperability between and among) the alphabet soup of LIMS, ELN, LES, SDMS, and supervisory packages has been the most significant trend in laboratory IT over the last half-dozen years. The goal is to automate the flow of...
Forbes  Jan 28  Comment 
Leave it to the Oatmeal, king of the Internet. When the ever-popular cartoonist took to Kickstarter to fund an upcoming card game called "Exploding Kittens," he was able to raise his modest $10,000 goal in a mere 20 minutes. It by no means stopped...




 

Elan Corporation (NYSE:ELN) is a biotechnology company that makes drugs to treat Alzheimer’s disease, multiple sclerosis, Crohn’s disease and severe bacterial infections.[1]

Company Overview

Elan's main revenue generators are now susceptible to generic competition and it has only one product in late-stage clinical trials. The company has admitted that its future depends on whether it can successfully develop and commercialize key pipeline drugs.[2]

Business & Financial Metrics[3]

In 2009, Elan incurred a net loss of $176.2 million on revenues of $1.11 billion. This represents a 148.2% increase in net loss and an 11.2% increase in total revenues from 2008, when the company lost $71.0 million on revenues of $1.00 billion.

Business Segments[4]

Elan Corporation's two business segments are Biopharmaceuticals and EDT.[1]

  • BioNeurology (75.2% of total revenues): The BioNeurology segment develops and commercializes of treatments for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Crohn’s disease, severe chronic pain and infectious diseases.[1] The segment currently has a total of 11 products in clinical development and 6 products that are marketed by either the company or its licensees. Its main products are Tysabri, Maxipime and Azactam (treatments for severe bacterial infection), Prialt (a treatment for sever chronic pain) and Bapineuzumab.[1]
  • EDT (14.3% of total revenues): The EDT segment develops systems to more efficiently deliver drugs to the body and licenses these systems to other pharmaceutical companies.[1] The segment currently has a total 17 products in clinical development and 22 products that are marketed by its licensees. Its main products are TriCor (in partnership with Abbott Laboratories), Ritalin (in partnership with Novartis AG), Rapamune (in partnership with Wyeth) and Emend (in partnership with Merck).[1]

Key Trends & Forces

Safety concerns over key drugs compel Elan Corporation to seek EDT sale

In August 2008, following renewed safety concerns related to Tysabri and Bapineuzumab, Elan Corporation decided to spin off EDT so as to leave the company more focused on its Biopharmaceuticals segment.[5] EDT lists ten out of the world's top twelve pharmaceutical companies among its clients, including Merck & Co., Wyeth and Abbott Laboratories. The company is currently accepting first round bids for EDT and hopes to successfully complete the sale of this unit for as much as $1.4 billion.[5]

Elan Corporation's dependence on collaborators like Biogen Idec and Wyeth

In the development and commercialization of its treatments, Elan Corporation collaborates extensively with other pharmaceutical companies, many of which are its competitors.[2] In fact, the company manufactures none of its four highest revenue generators under the biopharmaceuticals segment.[2] In the case of Bapineuzumab, the company shares all of its research and development costs with Wyeth.[2] In the case of Tysabri, Biogen Idec manufactures and distributes the drug in the European Union and the rest of the world while Elan Corporation buys it from Biogen Idec and distributes it in the United States.[2] Because the company shares both costs and revenues in all of these partnerships, it is bound by and susceptible to changes in the terms of each partnership agreement.

Competition

Biogen Idec makes drugs to treat autoimmune diseases, cancer and neurological diseases. The company's most important products are Avonex (a treatment for multiple sclerosis) and Rituxan (a treatment for non-Hodgkin's lymphoma.[6]

Merck & Co. is the seventh largest pharmaceutical company in the world by revenue. Although the company makes a wide range of drugs, the bulk of its revenues come from blockbuster products like Singulair (a treatment for asthma), Cozaar (a treatment for hypertension), Fosamax (a treatment for osteoperosis), Gardasil (a vaccine for the human papillomavirus) and ProQuad (a vaccine for measles, mumps, rubella and chicken pox).[7]

Novartis AG is the fifth largest pharmaceutical company in the world by revenue..[8] Although the company makes a wide range of drugs, the bulk of its revenues come from blockbuster products like Diovan (a treatment for hypertension), Sandostatin (a treatment for acromegaly), Gleevec and Zometa (treatments for certain types of cancer). In addition, Novartis AG is unique by virtue of its strong presence in the generic drugs market.[8]

Teva Pharmaceutical Industries is the world's largest generic drugs manufacturer by revenue. The company also filed more patent challenges than any other generic drugs manufacturer in the same year. Successful challenges gave the company exclusive rights to make patented products, like Zocor and Pravachol (cholesterol-lowering treatments) along with Zoloft and Wellbutrin XL (treatments for depression), for a period of six months.[9]

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 "Operating Review", Page 10, Annual Report (2007), Elan Corporation
  2. 2.0 2.1 2.2 2.3 2.4
  3. ELN 2009 20-F pg. 5  
  4. ELN 2009 20-F pg. 115  
  5. 5.0 5.1
  6. 8.0 8.1 "Selected Financial Data", Page 2, Annual Report (2007), Novartis AG

Kidney Infection Symptoms

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki